Login

Repare Therapeutics Inc. SEC Filings

Filed On Filing
14 May 2026 SCHEDULE 13G/A
19 Feb 2026 15-12G
30 Jan 2026 EFFECT
30 Jan 2026 Form 4: Bvf Partners L P/IL, 10% owner and 9 others

Disposed of 10,166,943 shares (Tender Offer)

30 Jan 2026 SCHEDULE 13D/A
28 Jan 2026 Form 4: Rhoads Ann D, Director

Returned 4,000 shares to the issuer

28 Jan 2026 Form 4: Forte Steve, EVP, CHIEF FINANCIAL OFFICER

Returned 56,786 shares to the issuer · Disposed of 1,110,800 Employee Stock Option (right to buy) (Disposition to Issuer)

28 Jan 2026 Form 4: Alves Sandra Isabelle Barros, SVP, Finance and CAO

Returned 31,622 shares to the issuer · Disposed of 50,500 Employee Stock Option (right to buy) (Disposition to Issuer)

28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 S-8 POS
28 Jan 2026 POS AM
28 Jan 2026 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more

Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.

28 Jan 2026 Form 4: Schafer Carol, Director

Returned 8,000 shares to the issuer · Disposed of 37,941 Stock Option (right to buy) (Disposition to Issuer)

28 Jan 2026 Form 4: Civik Thomas, Director

Returned 7,500 shares to the issuer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support